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Abstract
Background: Hepatic encephalopathy (HE) is an important neuropsychiatry complication of liver disease causing significant 
morbidity and mortality worldwide. Efforts at improving the outcome have resulted in development of new strategies in the 
management given the background of new insights in the pathogenesis of this disease entity. Understanding the disease 
profile including precipitants as well as prognostic factors will contribute in this regard as new strategies are yet to be widely 
applied. The aim of this report is to document the profile of patients with HE, the precipitants, prognostic factors as well as 
the scope of the burden associated with it.
Materials and Methods: In this prospective study, all patients managed for HE from January to December 2008 were 
recruited. A questionnaire was used to extract their basic demographics, clinical features noting any possible precipitants, 
complications, management protocol as well as outcome.
Results: A total of 21 subjects (11 females and 10 males) within the age range of 16–83 years were seen during the period under 
review. (mean age 57.9 ± 13). There was no significant difference in the mean ages of males and females. Two patients 
had acute encephalopathy, while others had acute-on chronic encephalopathy. The risk factors for liver disease included 
significant alcohol ingestion, hepatitis B virus infection, and previous jaundice, while other complications of liver disease noted 
were deepening jaundice, ascites, bleeding tendencies, and renal failure. The identified precipitants for HE were sepsis 6 
(29%), electrolyte inbalance 3 (14%), gastrointestinal bleed 5 (24%), drugs (5%), and possible malignant transformation 6 
(29%). Focus of sepsis was bacterial peritonitis in two cases. Majority of our patients (61%) came during advanced stage of 
liver disease (Child-Pugh class C). Length of hospital stay ranged from 1 to 7 weeks and a mortality of 48% was observed. 
Predictors of mortality were a history of significant alcohol ingestion, previous blood transfusion, Hepatitis B and C infections, 
and severe liver dysfunction on presentation (Child-Pugh class C).
Conclusions: HE is associated with a high mortality rate and this scenario is associated with a history of previous blood 
transfusion, Hepatitis B and C infections, and severe liver dysfunction on presentation. Measures to reduce the burden of 
viral Hepatitis B and C, safe blood transfusion, and responsible use of alcohol should be promoted. Screening of those at 
risk of encephalopathy (liver disease patients) with a psychometric test of good predictability should be part of their routine 
evaluation in daily practice so as to detect cases of latent encephalopathy. Intensive care facilities and necessary personnel 
should be provided.
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Introduction
Hep a t i c  en cep h a lo p a t h y  ( HE )  i s  a  co m m o n 
neuropsychiatric syndrome seen in patients with 
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significant hepatic dysfunction in the absence of 
neurological disorders.[1] It is seen in upto 30-45% of 
patients with cirrhosis and its latent or sub clinical 
form (minimal hepatic encephalopathy can affect 
upto 60% of patients with liver disease.[2] Although 
controversy about the exact pathogenetic mechanism 
exists, certain factors like hyper ammonia and increased 
blood-brain permeability to ammonia, increased brain 
concentration of manganese and inhibitory neurosteroids 
(allopregnanolone) have been documented.[3] Based on 
the underlying hepatic abnormality, encephalopathy is 
subdivided into three types;[1] type A (associated with 
acute liver disease), type B (associated with portosystemic 
bypass and no intrinsic hepatocellular disease), and type 
C (associated with chronic liver disease).
Current recommendation[1] of the working party on its 
definition suggest guidelines that would allow even the 
diagnosis of the sub clinical form (latent encephalopathy) 
and the use of the newer neuroimaging techniques. 
However, this is yet to be widely applied in clinical practice 
as some report indicates.[4] Available reports[4-6] have 
identified factors such as sepsis, gastrointestinal bleeding, 
constipation, and diuretic use as common precipitating 
factors of encephalopathy in patients with liver disease. 
Identification of these precipitants and other prognostic 
indices would enable institution of more rationale 
measures in the management of this condition, which 
has been associated with poor outcome.[7] This is even 
worse in resource poor countries that often lack necessary 
manpower, newer imaging techniques, and dedicated 
specialized care unit. The cornerstone of therapy is still the 
nonabsorbable disaccharides, since the new therapeutic 
agents with broad-spectrum activity against urease 
producing bacteria are yet to be available. Also, dietary 
manipulation is still protein restriction and not protein 
maintenance with glutein and casein-free diet (GCFD), 
which has recently been recommended in view of its role 
in lowering opioid peptides that have been implicated in 
the pathogenesis.
An earlier report[6] from this locality in children had shown 
a very poor outcome (95% mortality), although these were 
mostly fulminant cases (type A encephalopathy). There is 
a need to document the pattern of hepatic encephalopathy 
in adult population in our setting as only reports from 
resource-endowed countries abound in the literature. 
This will no doubt allow a more appropriate management 
guideline-taking cognizance of resource availability. We 
therefore set out to redress this issue in our study. The 
aim of this report is documenting the profile of patients 
admitted with features of HE from January to December 
2008 and note possible precipitants, complications, and 
management outcome.
Materials and Methods
This was a prospective and observational study and was 
conducted in line with the principle of the Declaration of 
Helsinki as amended in Tokyo (1975), Venice (1983), and 
Hong Kong (1989). All patients with HE admitted into 
the Medical Wards of the Lagos State University Teaching 
Hospital, Ikeja from January to December 2008 were recruited. 
A patient was included if he had impaired consciousness with 
a background liver disease (acute or chronic on basis of 
clinical findings, liver biochemistry, and sonographic findings) 
in the absence of any neurological disorder or other cause of 
impaired consciousness. A questionnaire was used to extract 
the following: Bio data, clinical features including laboratory 
findings, any identified precipitants, complications as well as 
management and outcome. Brain imaging with computerized 
tomographic scan was done where possible to exclude primary 
neurological cause. Diagnosis of spontaneous bacterial 
peritonitis was based on demonstration of more than 250 
WBC/cm3 in ascitic fluid. The presence of elevated serum 
creatinine (>1.5 mg/dl) in the absence of shock, hematuria, 
or proteinuria with a normal renal sonogram was taken to be 
indicative of hepatorenal syndrome. The Child-Pugh scoring 
system[7] was used for assessing the severity of liver disease on 
patient presentation. The scoring system takes into account 
the serum albumin, serum prothrombin time, and bilirubin 
as well as presence of fluid retention and encephalopathy; 
each of which is given a numerical score. There are 3 grades: 
A, B, and C depending on the total scores. The West Haven 
criteria[8] was used in grading the encephalopathy. It is a 
semi-quantitative grading of mental state from trivial lack 
of awareness (grade 1) to coma (unresponsive to verbal or 
noxious stimuli (grade 4).
Results
There were 21 subjects (11 females and 10 males) with HE 
seen within the period of study. Age ranged from 16 to 83 
years with a median age of 61 years. The mean age of the 
study subjects was 57.9 ± 13 years, and the mean age of 
the males and females were comparable [(57.7 (±18) years 
vs. 58 (±8) years; P = 0.7]. Total emergency admission for 
the gastroenterology/liver unit during this period was 362, 
thus, HE accounted for 6% of this.
Two patients had acute encephalopathy (type A), while 19 
had acute on chronic liver disease (type C). The two acute 
encephalopathy were drug induced, one of whom survived.
Risk factors for chronic liver disease
Significant alcohol and previous blood transfusion histories 
were documented in 10 (48%) and 2 (10%), respectively, of 
the study subjects. Also, a history of previous jaundice and 
use of herbal medications was documented in 9 (43%) and 
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2 (10%), respectively, of the subjects under study.
These and other risk factors are shown in Table 1.
Clinical presentation
Of the stigmata of chronic liver disease, 4 (40%) of the 
males had testicular atrophy. The distribution of stigmata 
of chronic liver disease (CLI) is shown in Figure 1.
Some of the patients presented with complications of CLD 
and the distribution of these are shown in Figure 2.
Severity of liver disease on presentation as assessed using 
the Child-Pugh’s classification is shown in Figure 3.
Grading of HE
Table 2 shows the distribution of the grade of encephalopathy 
and outcome of management among study participants.
Precipitating factors
Identified precipitants of encephalopathy in the patients 
were sepsis 6 (29%), electrolyte inbalance 3 (14%), 
gastrointestinal bleed 5 (24%), drug induced (5%), and 
possible malignant transformation 6 (29%). Focus of sepsis 
was bacterial peritonitis in two cases.
Treatment and duration of hospitalization
Treatment type varied and included the use of mannitol, 
especially in acute encephalopathy. Various treatment types 
are shown in Table 3. The duration of hospitalization is 
shown in Table 4.
Outcome of management
In all, 10 (48%) of the subjects expired. The number of females 
who passed away was more than males, with the female: Male 
ratio being 7:3. Possible determinants of mortality are shown 
in Table 5. A history of significant alcohol ingestion, previous 
blood transfusion, Hepatitis B and C infections, and severe 
liver dysfunction on presentation (Child-Pugh class C) are 
highly predictive of mortality from encephalopathy.
Discussion
HE remains an important complication of liver disease 
associated with high mortality even in developed nations. 
Table 1: Clinical characteristics of the study subjects
Variable Frequency (%)
Previous blood transfusion 2 (10)
Alcohol history 10 (48%)
Hep C antibody 2 (10)
Hep B surface antigen 10 (48)
Previous jaundice 9 (43)
Elevated alpha feto protein (>100) 5 (29)
Use of herbs 2 (10)
Table 2: Grade of hepatic encephalopathy using West 
Haven criteria and outcome
Grade Frequency (%) Recovered (%) Died
1 11 (52.4) 7 (64) 4 (36%)
2 6 (28.6) 4 (67) 2 (33)
3 1 (4.8) 0 1 (100%)
4 3 (14.3) 0 3 (100%)
Table 3: Treatment modalities for hepatic 
encephalopathy
Variable Frequency (%)
Protein restriction 21 (100)
Lactulose 18 (86)
Metronidazole 18 (86)
Neomycin 4 (19)
Mannitol 18 (86)
Figure 3:	Child-Pugh's	classification	in	study	subjectsFigure 2: Distribution of complications of CLD
Figure 1: Prevalence of stigmata of CLD
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Newer insight into its pathogenesis[4] has led to newer 
approaches[9,10] in its management, though these are yet to 
be widely applied particularly in the resource poor nations.[3] 
Documentation of its profile including precipitating factors 
will go a long way in formulating rational strategies in its 
management including prophylaxis in view of the reported 
poor outcome.[11]
Majority of the patients in our study had encephalopathy 
complicating underlying chronic liver disease with only 
two having fulminant failure, one of whom survived. 
About half of study subjects had Hepatitis B-related liver 
disease, while significant alcohol consumption was noted 
in majority, which may have contributed to the progression 
of liver disease. This is in keeping with earlier reports[12] 
about the role of hepatitis B in causation of liver disease 
in our setting. Efforts at improving the coverage of current 
immunization campaign[13] against Hepatitis B certainly 
will help reduce the burden of Hepatitis B virus infection, 
whilst promotion of sensible use of alcohol should be 
encouraged.
The observed precipitants in this study, sepsis (29%), 
electrolyte inbalance (14%), gastrointestinal bleed (24%), 
drug induced (5%), and possible malignant transformation 
(29%), do not differ from those in previous reports.[3,5] No 
other precipitants were found in 5 (29%) with sonographic 
features of PLCC as well as elevated alpha fetoprotein 
and were considered as having PLCC.[14] Majority of our 
patients came in fairly advanced stage of liver dysfunction 
(Child-pugh class B and C), which may have contributed 
to observed mortality [Odds ratio (OR) 2.7 (95% CI) 
0.56-13.28). Higher fatality rate were recorded with 
increasing severity of encephalopathy (OR 5.1, 95% CI).
It is noteworthy that our management protocol (nonabsorbable 
disaccharides, antibiotics, and protein restriction) did not 
involve any of the newer therapeutic regime (antibiotics 
with broad spectrum activity against urease producing 
bacteria as well as GCFD). The patients in this study were 
nursed in the open ward and this was largely due to financial 
constraints. In our setting, usually healthcare costs are borne 
by the patients and payment often has to be made before 
some facilities are made available for use. Management in 
an intensive care unit as well as employment of the newer 
therapeutic measures may have improved the outcome.
Apart from advanced stage presentation, other predictors 
of fatal outcome are; severe grade of encephalopathy, a 
history of significant alcohol ingestion, previous blood 
transfusion, Hepatitis B and C infections. Identification of 
early encephalopathy by screening of those at risk (patients 
with pre-existing liver disease) using the psychometric 
tests[15,16] will go a long way in reducing the fatal outcome 
since advanced stage presentation as was documented in 
this study is associated with less favourable outcome.
Due to the high cost of imaging patients in this study, we 
did not have brain computerized tomographic scan (CT 
scan) to exclude primary neurological disease. However, 
most of these patients already had pre-existing liver 
disease.
The limitations of this report include a small sample size.
Conclusions
The disease burden of HE is high and the contributory 
factors of this scenario are potentially remediable. Possible 
measures that may ameliorate the dismal statistics 
associated with HE include routine vaccination against 
viral Hepatitis B and C, ensuring safe blood transfusion 
as well as responsible use of alcohol. Screening of those 
at risk of encephalopathy (liver disease patients) with a 
psychometric test of good predictability should be part of 
their routine evaluation in daily practice so as to detect 
cases of latent encephalopathy. Intensive care facilities 
and necessary personnel should be provided for the care 
of these patients in health institution.
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